VITA 34 Beheer

Beheer criteriumcontroles 2/4

VITA 34's CEO is Jakub Baran, appointed in Mar 2022, has a tenure of 2.67 years. directly owns 2.9% of the company’s shares, worth €2.19M. The average tenure of the management team and the board of directors is 2.7 years and 4.3 years respectively.

Belangrijke informatie

Jakub Baran

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	2.7yrs
Eigendom CEO	2.9%
Management gemiddelde ambtstermijn	2.7yrs
Gemiddelde ambtstermijn bestuur	4.3yrs

Recente managementupdates

VITA 34 AG's (ETR:V3V) CEO Compensation Looks Acceptable To Us And Here's Why

Dec 07

How Is VITA 34's (ETR:V3V) CEO Compensated?

Dec 18

Recent updates

Earnings Miss: VITA 34 AG Missed EPS By 29% And Analysts Are Revising Their Forecasts

Apr 03

VITA 34 AG's (ETR:V3V) Intrinsic Value Is Potentially 56% Above Its Share Price

Mar 25

Should You Be Adding VITA 34 (ETR:V3V) To Your Watchlist Today?

Mar 10

Here's Why VITA 34 (ETR:V3V) Can Manage Its Debt Responsibly

Feb 22

Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?

Feb 05

Can Mixed Financials Have A Negative Impact on VITA 34 AG's 's (ETR:V3V) Current Price Momentum?

Jan 18

Did You Participate In Any Of VITA 34's (ETR:V3V) Fantastic 201% Return ?

Jan 02

How Is VITA 34's (ETR:V3V) CEO Compensated?

Dec 18

Should You Be Adding VITA 34 (ETR:V3V) To Your Watchlist Today?

Dec 01

CEO

Jakub Baran

2.7yrs

Tenure

Mr. Jakub Julian Baran serves as Chairman of the Management Board and Chief Executive Officer at VITA 34 AG since March 22, 2022. He serves as Member of the Supervisory Board at Betacom S.A. since May 2019...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jakub Baran	Chairman of the Management Board & CEO	2.7yrs	geen gegevens	2.9% € 2.2m
Tomasz Baran	Vice President of the Management Board & Chief Commercial Officer	2.7yrs	geen gegevens	0.70% € 533.0k
Thomas Pfaadt	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Santiago Luengo	Managing Director of Secuvita	no data	geen gegevens	geen gegevens

2.7yrs

Gemiddelde duur

Ervaren management: V3V's management team is considered experienced (2.7 years average tenure).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Isadore Ances	Member of Scientific & Medical Advisory Board	no data	geen gegevens	geen gegevens
A. Bader	Member of Scientific & Medical Advisory Board	no data	geen gegevens	geen gegevens
Robert Iannone	Member of Scientific & Medical Advisory Board	no data	geen gegevens	geen gegevens
W. Holzgreve	Member of Scientific & Medical Advisory Board	no data	geen gegevens	geen gegevens
Carlo Croce	Member of Scientific & Medical Advisory Board	no data	geen gegevens	geen gegevens
Jack Goldberg	Member of Scientific & Medical Advisory Board	no data	geen gegevens	geen gegevens
E. Wunder	Member of Scientific & Medical Advisory Board	no data	geen gegevens	geen gegevens
Ronald Wapner	Member of Scientific & Medical Advisory Board	no data	geen gegevens	geen gegevens
Zbigniew Mrowiec	Member of Scientific & Medical Advisory Board	no data	geen gegevens	geen gegevens
Florian Schuhbauer	Deputy Chairman of the Supervisory Board	4.3yrs	€20.00k	geen gegevens
Alexander Granderath	Chairman of Supervisory Board	2.9yrs	geen gegevens	geen gegevens
Frank Kohler	Independent Member of the Supervisory Board	7.4yrs	€30.00k	geen gegevens

4.3yrs

Gemiddelde duur

Ervaren bestuur: V3V's board of directors are considered experienced (4.3 years average tenure).

VITA 34 Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

VITA 34 AG, Annual General Meeting, Jun 29, 2022

VITA 34 AG's (ETR:V3V) CEO Compensation Looks Acceptable To Us And Here's Why

VITA 34 AG, Annual General Meeting, Jun 30, 2021

How Is VITA 34's (ETR:V3V) CEO Compensated?

Recent updates

Second quarter 2024 earnings released: €0.10 loss per share (vs €0.07 loss in 2Q 2023)

Consensus estimates of losses per share improve by 33%

First quarter 2024 earnings released: €0.05 loss per share (vs €0.18 loss in 1Q 2023)

Price target increased by 15% to €6.00

No longer forecast to breakeven

VITA 34 AG to Report Q1, 2024 Results on May 31, 2024

New minor risk - Share price stability

New minor risk - Profitability

Why We're Not Concerned About VITA 34 AG's (ETR:V3V) Share Price

New minor risk - Shareholder dilution

Revenues Tell The Story For VITA 34 AG (ETR:V3V) As Its Stock Soars 26%

Third quarter 2023 earnings released: €0.10 loss per share (vs €0.02 loss in 3Q 2022)

Is VITA 34 (ETR:V3V) Using Too Much Debt?

Second quarter 2023 earnings released: €0.07 loss per share (vs €0.30 loss in 2Q 2022)

Is VITA 34 (ETR:V3V) Using Debt In A Risky Way?

Consensus EPS estimates fall by 28%, revenue upgraded

New minor risk - Share price stability

New minor risk - Market cap size

First quarter 2023 earnings released: €0.18 loss per share (vs €0.18 loss in 1Q 2022)

Vita 34 Ag Starts Recruitment for Clinical Trial with Car-T Drug Candidate

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Is VITA 34 (ETR:V3V) Using Debt In A Risky Way?

VITA 34 AG to Report Q3, 2023 Results on Nov 21, 2023

Consensus estimates of losses per share improve by 10%

Third quarter 2022 earnings released: €0.02 loss per share (vs €0.11 profit in 3Q 2021)

Price target decreased to €10.50

Second quarter 2022 earnings released: EPS: €0.30 (vs €0.002 loss in 2Q 2021)

VITA 34 AG Revises Earnings Guidance for the Financial Year 2022

VITA 34 AG to Report Q2, 2022 Results on Aug 30, 2022

VITA 34 AG, Annual General Meeting, Jun 29, 2022

Consensus EPS estimates fall by 85%

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

VITA 34 AG to Report Q1, 2022 Results on May 31, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Vita 34 Ag Provides Revenue Guidance for the Financial Year 2022

Price target increased to €25.00

Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?

Price target increased to €21.10

VITA 34 AG's (ETR:V3V) CEO Compensation Looks Acceptable To Us And Here's Why

Third quarter 2021 earnings released: EPS €0.14 (vs €0.18 in 3Q 2020)

Second quarter 2021 earnings released

Consensus forecasts updated

VITA 34 AG (XTRA:V3V) entered into a Business Combination Agreement to acquire Polski Bank Komórek Macierzystych S.A. (WSE:BKM) (PKBM) from AOC Health GmbH, Jakub Baran, Tomasz Baran and others for approximately PLN 840 million.

First quarter 2021 earnings released

VITA 34 AG Provides Earnings Guidance for the Year 2021

Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?

Consensus EPS estimates fall to €0.47

Earnings Miss: VITA 34 AG Missed EPS By 29% And Analysts Are Revising Their Forecasts

Full year 2020 earnings released: EPS €0.37 (vs €0.18 in FY 2019)

VITA 34 AG's (ETR:V3V) Intrinsic Value Is Potentially 56% Above Its Share Price

VITA 34 AG to Report Q1, 2021 Results on May 11, 2021

Should You Be Adding VITA 34 (ETR:V3V) To Your Watchlist Today?

Here's Why VITA 34 (ETR:V3V) Can Manage Its Debt Responsibly

New 90-day high: €13.95

Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?

New 90-day high: €13.05

Can Mixed Financials Have A Negative Impact on VITA 34 AG's 's (ETR:V3V) Current Price Momentum?

Did You Participate In Any Of VITA 34's (ETR:V3V) Fantastic 201% Return ?

VITA 34 AG, Annual General Meeting, Jun 30, 2021

How Is VITA 34's (ETR:V3V) CEO Compensated?

Should You Be Adding VITA 34 (ETR:V3V) To Your Watchlist Today?

Price target raised to €17.50

Revenue and earnings miss expectations

Third quarter 2020 earnings released: EPS €0.18

New 90-day low: €11.20

Earnings released

VITA 34 AG to Report Q2, 2020 Results on Aug 27, 2020

New 90-day low - €11.70

AOC Health GmbH acquired a 27.3% stake in VITA 34 AG (XTRA:V3V).

CEO

Tenure